MX370858B - Composiciones que comprenden péptidos de gliadina para usarse en el tratamiento de cáncer. - Google Patents

Composiciones que comprenden péptidos de gliadina para usarse en el tratamiento de cáncer.

Info

Publication number
MX370858B
MX370858B MX2015011833A MX2015011833A MX370858B MX 370858 B MX370858 B MX 370858B MX 2015011833 A MX2015011833 A MX 2015011833A MX 2015011833 A MX2015011833 A MX 2015011833A MX 370858 B MX370858 B MX 370858B
Authority
MX
Mexico
Prior art keywords
cancer
patient
kits
tyrosine kinase
administering
Prior art date
Application number
MX2015011833A
Other languages
English (en)
Other versions
MX2015011833A (es
Inventor
L Shaw Fred
Original Assignee
Barmarsa Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barmarsa Res Llc filed Critical Barmarsa Res Llc
Publication of MX2015011833A publication Critical patent/MX2015011833A/es
Publication of MX370858B publication Critical patent/MX370858B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición que comprende un péptido de gliadina para usarse en el tratamiento de cáncer en un paciente, en donde el cáncer es cáncer pulmonar de células no pequeñas.
MX2015011833A 2013-03-07 2014-03-07 Composiciones que comprenden péptidos de gliadina para usarse en el tratamiento de cáncer. MX370858B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774285P 2013-03-07 2013-03-07
PCT/US2014/021660 WO2014138556A1 (en) 2013-03-07 2014-03-07 Kits and methods for the treatment of cancer using gliadin peptides

Publications (2)

Publication Number Publication Date
MX2015011833A MX2015011833A (es) 2016-06-02
MX370858B true MX370858B (es) 2020-01-08

Family

ID=50483486

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011833A MX370858B (es) 2013-03-07 2014-03-07 Composiciones que comprenden péptidos de gliadina para usarse en el tratamiento de cáncer.

Country Status (15)

Country Link
US (2) US9254308B2 (es)
EP (1) EP2964242B1 (es)
JP (1) JP6352952B2 (es)
KR (1) KR102230514B1 (es)
CN (2) CN105120881A (es)
AU (1) AU2014225496B2 (es)
BR (1) BR112015021448B1 (es)
CA (1) CA2903471C (es)
DK (1) DK2964242T3 (es)
HK (1) HK1212920A1 (es)
IL (1) IL241230B (es)
MX (1) MX370858B (es)
NZ (1) NZ711682A (es)
SG (1) SG11201506963UA (es)
WO (1) WO2014138556A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312810B (zh) * 2017-07-11 2020-10-09 南开大学 酶催化苯丁酸氮芥-多肽水凝胶的制备及抗癌应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729296B1 (fr) * 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
WO2003053332A2 (en) 2001-08-20 2003-07-03 Myriad Genetics, Inc Composition and method for treating viral infection
JP2004099459A (ja) * 2002-09-05 2004-04-02 Asama Chemical Co Ltd 抗腫瘍剤
AU2003266376A1 (en) 2003-09-01 2005-03-16 Galapagos Genomics N.V. Polypeptides and polynucleotides for use as a medicament
WO2009137572A2 (en) * 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
AU2011295919A1 (en) * 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
WO2014002108A1 (en) * 2012-06-27 2014-01-03 Amrita Vishwa Vidyapeetham University A core-shell nanostructure on the basis of proteins with corresponding therapeutic agents

Also Published As

Publication number Publication date
IL241230A0 (en) 2015-11-30
AU2014225496A1 (en) 2015-09-24
EP2964242A1 (en) 2016-01-13
CN105120881A (zh) 2015-12-02
IL241230B (en) 2021-02-28
AU2014225496B2 (en) 2018-03-15
KR102230514B1 (ko) 2021-03-19
US9254308B2 (en) 2016-02-09
CN118217382A (zh) 2024-06-21
DK2964242T3 (en) 2019-03-04
US20140256647A1 (en) 2014-09-11
US9669068B2 (en) 2017-06-06
JP2016529202A (ja) 2016-09-23
WO2014138556A1 (en) 2014-09-12
KR20150138230A (ko) 2015-12-09
US20160143991A1 (en) 2016-05-26
JP6352952B2 (ja) 2018-07-04
CA2903471C (en) 2022-11-01
BR112015021448A2 (pt) 2017-10-10
CA2903471A1 (en) 2014-09-12
EP2964242B1 (en) 2018-11-14
NZ711682A (en) 2021-07-30
SG11201506963UA (en) 2015-10-29
MX2015011833A (es) 2016-06-02
HK1212920A1 (zh) 2016-06-24
BR112015021448B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
PH12016502355B1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2016001793A (es) Terapia de combinacion para el tratamiento del cancer.
MX2017013142A (es) Terapia combinada para tratar cáncer.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
TW201613577A (en) Pharmaceutical combinations
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
WO2015035410A8 (en) Cancer therapy

Legal Events

Date Code Title Description
FG Grant or registration